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ABSTRACT
Background    The addition of chemotherapy to en-
docrine therapy for luminal A breast cancer generally 
provides little benefit. However, the least benefit of che-
motherapy in all patients with luminal A breast cancer is 
controversial. 
Methods    This was a retrospective study of 140 pa-
tients with luminal A breast cancer who underwent 
surgery at Tottori University Hospital between 2001 and 
2010. Luminal A breast cancer was defined as positive 
for estrogen receptors and/or progesterone receptors and 
negative for human epidermal growth factor 2. Postop-
erative endocrine therapy was given to all patients. The 
prognostic values of age, tumor size, presence of lym-
phovascular invasion and lymph node status were evalu-
ated. In addition, the prognostic value of chemotherapy 
for patients with identified risk factors affecting relapse-
free survival and overall survival was evaluated. 
Results    Tumor size greater than 2 cm and positive 
lymph node status were factors significantly affecting 
relapse-free survival. There were no factors significantly 
affecting overall survival. There was no significant dif-
ference in the relapse-free survival of patients with tu-
mor size greater than 2 cm and/or positive lymph node 
status who either received chemotherapy or not. How-
ever, the relapse event was earlier in patients with tumor 
size greater than 2 cm and positive lymph node status 
who did not receive chemotherapy than in those who re-
ceived chemotherapy. 
Conclusion    Chemotherapy could provide little benefit 
to patients with luminal A breast cancer. However, che-
motherapy may bring them longer relapse-free periods. 
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Luminal A breast cancers that express estrogen recep-
tors (ERs) and/or progesterone receptors (PRs) and are 
negative for human epidermal growth factor receptor 2 
(HER2) expressions respond well to endocrine therapy 
and have a generally favorable prognosis. Patients 
with luminal A breast cancers are not so sensitive to 
paclitaxel- and doxorubicin-containing preoperative 
chemotherapy.1 Patients with node-positive luminal A 
breast cancer gain little benefit from taxane therapy 
administered.2, 3 Proceedings from the 12th St. Gallen 
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International Breast Cancer Conference held in 2011 
showed that the luminal A subtype was fairly unrespon-
sive to chemotherapy and said that node positivity per se 
was not an indication for use of chemotherapy, although 
a large majority of physicians would use it if more than 
3 axillary lymph nodes were involved.4 However, the 
least benefit of chemotherapy in all patients with lumi-
nal A breast cancer is controversial. The 11th St. Gallen 
Conference held in 2009 presented the relative indica-
tions for using endocrine therapy alone or a combination 
of chemotherapy and endocrine therapy for luminal A 
breast cancer.5 The clinicopathological risk factors for 
prognosis included lymph node status, tumor size, pres-
ence of lymphovascular invasion, histological grade, and 
proliferative status. Therefore, it is essential to clarify the 
significance of chemotherapy for patients with these risk 
factors and luminal A breast cancer. In this report, we 
analyzed the significance of chemotherapy for patients 
with luminal A breast cancer who underwent surgery 
and received postoperative endocrine therapy.
 
SUBJECTS AND METHODS
Patients
A total of 140 patients with initial luminal A primary 
invasive breast cancers who underwent surgery in our 
department at Tottori University Hospital between June 
2001 and December 2010 were retrospectively investi-
gated (Table 1). Men with breast cancer, women with in 
situ carcinoma, bilateral breast carcinoma or who un-
derwent neoadjuvant chemotherapy or chemotherapy for 
another disease were excluded from the study. Informed 
consent was obtained from every patient. Patients were 
treated with breast-conserving surgery or mastectomy. 
All patients received post-operative endocrine therapy 
(Table 2). Most patients with breast-conserving surgery 
received radiotherapy to the whole breast after surgery. 
There were 24 patients who received chemotherapy (Ta-
ble 2). Decisions regarding chemotherapy were made by 
the treating physician on the basis of patient preference 
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and risk factors. In principle, the chemotherapy regimen 
was as follows: FEC (fluorouracil 500 mg/m2, epirubicin 
60 mg/m2 and cyclophosphamide 500 mg/m2) alone on 
day 1 every 3 weeks for 4 cycles or FEC (fluorouracil 
500 mg/m2, epirubicin 60 mg/m2 and cyclophosphamide 
500 mg/m2) on day 1 every 3 weeks for 4 cycles fol-
lowed by docetaxel (60 mg/m2) on day 1 every 3 weeks 
for 4 cycles or paclitaxel (80 mg/m2) on day 1 and 8 ev-
ery 3 weeks for 4 cycles. 
 
Histopathological and immunohistochemical eval-
uations
All histopathological and immunohistopathological 
diagnoses were determined by several pathologists at 
our facilities or at another laboratory facility within our 
partnership. Surgical specimens were embedded in par-
affin, sectioned and stained with hematoxylin and eosin. 
Luminal A subtype was defined as ER and/or PR posi-
tive and HER2 negative. If the Ki-67 labeling index and/
Table 1. Patients characteristics
 
 Median [range] Number (%)
 
Age (yr)  60.5  [34–86]
Menstruation status  Premenopause   39 (28%)
 Postmenopause   101  (72%)
Surgical procedure  Mastectomy   39  (28%)
 Breast-conserving surgery   101  (72%)
Tumor size (cm)  1.7 [0.5–5.3]
ER positivity proportion (%)   90 [15–95]
PR positivity proportion (%)   60 [0–95]
Lymphovascular invasion Negative   37  (27%)
 Positive   101  (72%)
 Unkown   2  (1%)
Nuclear grade Grade 1     52 (37%)
 Grade 2    54  (39%)
 Unkown   34  (24%)
Ki67 < 14%   18  (13%)
 Unknown   122  (87%)
Lymph node metastasis status Negative   103  (74%)
 Positive   37  (26%)
Lymph node metastasis number*  2 [1–18]
* Number in 37 positive cases.
 ER, estrogen receptor; PR, progesterone receptor.  
Table 2. Adjuvant systemic therapy
 Number (%)
Endocrine therapy [n = 140] Tamoxifen ± LH-RH agonist 48 (34%)
 Aromatase inhibitor 75 (54%)
 Tamoxifen ± LH-RH agonist  Aromatase inhibitor 15 (10%)
 Aromatase inhibitor  Tamoxifen  1 (1%)
 Toremifene citrate 1 (1%)
 
Chemotherapy [n = 24] Anthracyclin 19 (79%)
 Anthracyclin + Taxane 5 (21%)
 
LH-RH, luteinizing hormone-releasing hormone.
or nuclear grade were determined, 
the luminal A subtype was also 
defined as low Ki-67 labeling in-
dex (< 14%) and/or nuclear grade 
1 or 2. ER and PR positivity was 
confirmed by immunohistochem-
istry (IHC); greater than 10% 
of tumors cells staining positive 
was considered positive. HER2-
negative-status was confirmed by 
IHC (with 0, 1+, 2+ scores indicat-
ing no cells with staining, < 10% 
of cells with membrane staining, 
or > 10% of cells with low or me-
dium membrane staining, respec-
tively). Tumors that were 2+ by 
IHC were also examined by fluo-
rescence in situ hybridization (with 
an amplification ratio < 2.0 indi-
cating negative status). The Ki-67 
labeling index was determined by 
IHC.
 
Statistics
Relapse-free survival was defined as the period from 
the date of operation to the date of the first confirma-
tion of relapse (i.e., local relapse or metastasis) or death 
from any cause, whichever came first. Overall survival 
was defined as the period from the date of operation 
to the date of death from any cause. Relapse-free and 
overall survival periods were estimated with the Kaplan-
Meier method and compared with the log-rank test and 
Wilcoxon test. The Mann-Whitney U test was used for 
comparisons of continuous outcomes, while the chi-
square test, for comparisons of categorical variables. 
Risk factors affecting prognosis were estimated with 
univariate and multivariate analyses. Cox’s proportional-
hazards model was applied in multivarate analysis. Dif-
ferences were considered significant when the P value 
was < 0.05.   
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Table 3. Comparion between chemotherapy and non-chemotherapy groups
Factor Chemotherapy group Non-chemotherapy group P value
 n = 24 n = 116
Number of lymph node metastasis  Median [range] 1.5 [0–18] 0 [0–8] < 0.01
Tumor size (cm)  Median [range]  2.5 [1.2–4.5] 1.5 [0.5–5.3] < 0.01
Lymphovascular invasion Positive: number (%) 23 (96%) 78 (67%) < 0.01
 Negative: number (%) 1 (4%) 36 (31%)
 Unknown: number (%)   2 (2%)
Age (yr) Median [range] 52 [34–74] 62 [37–86] < 0.01
Event Relapse: number (%)  4 (16%) 6 (5%) 0.06
 Death: number (%)  2 (8%) 3  (2.5%) 0.2
 
RESULTS
Patient characteristics
Table 1 shows the characteristics of 140 luminal A 
breast cancer patients. The median patient age was 60.5 
years (range: 34–86 years). Menstruation status of 39 
(28%) patients was premenopausal and that of 101 (72%) 
patients was postmenopausal. There were 101 (72%) 
patients receiving breast-conserving surgery and 39 
(28%) patients receiving mastectomy. The median tumor 
size was 1.7 cm (range: 0.5–5.3 cm), and 103 patients 
(74%) were free of axillary lymph node metastasis. In 
37 patients with axillary lymph node metastasis, the 
median number of involved lymph nodes was 2 (range: 
1–18). Median ER and PR positivity proportion of tu-
mor cells in each tumor were 90% (range: 15–95%) and 
60% (range: 0–95%) respectively. There were 101 (72%) 
patients positive for lymphovascular invasion. There 
were 52 (37%) and 54 (39%) patients with nuclear-grade 
tumors of 1 and 2, respectively. The median follow-up 
period was 40 months (range: 3–113 months). 
Adjuvant systemic therapy
Table 2 lists the post-operative systemic therapies. All 
patients received some type of endocrine therapy. A total 
of 48 (34%) patients received tamoxifen and/or a lutein-
izing hormone-releasing hormone agonist, and 75 (54%) 
patients received an aromatase inhibitor. There were 15 
(10%) patients who changed from tamoxifen and/or lu-
teinizing hormone-releasing hormone agonist to the aro-
matase inhibitor for the following reasons: change from 
pre- to post-menopausal in 9 patients, patient preference 
to continue endocrine therapy after 5 years of treatment 
with 1 type of therapy in 3, thrombosis in 1, uterine en-
dometrial hypertrophy in 1, and uterine cancer in 1 pa-
tients. One patient changed from the aromatase inhibitor 
to tamoxifen because of joint pain. 
 A total of 24 patients received chemotherapy. Che-
motherapy was performed more frequently to patients 
with metastases involving several lymph nodes, large 
tumor size, positive lymphvascular invasion and younger 
age (Table 3). Relapse events were 4 (16%) in the che-
motherapy group and 6 (5%) in the non-chemotherapy 
group, and intergroup difference was not significant (P = 
0.06) (Table 3). Death events, 2 (8%) in the chemothera-
py group and 3 (2.5%) in the non-chemotherapy group, 
showed no significance (P = 0.20) (Table 3). Of 24 
chemotherapy-based patients, 19 (79%) patients received 
anthracycline alone, and the remaining 5 (21%) received 
anthracycline and taxane (Table 2). Chemotherapy that 
included taxane was adopted more frequently in patients 
with metastases involving several lymph nodes: median 
number of involved nodes (range) was 1 (0–13) when the 
agent was anthracycline, and 11 (3–18) when taxane was 
coadministered. 
Risk factors associated with relapse and death
Relapse or death risk factors were investigated by uni-
variate analysis among positive lymph node status, tu-
mor size > 2 cm, positive lymphovascular invasion and 
age < 40 years old. As the result, positive lymph node 
status and tumor size > 2 cm were significant relapse 
Table 4. Relapse-free survival and overall survival in 140 patients with luminal A breast cancer (univariate analysis)
 Relapse-free survival  Overall survival
 Univariate analysis  Univariate analysis
 Hazard 95% Confi-  P  Hazard 95% Confi-  P
 ratio dence interval value ratio dence interval value
Lymph node status (positive versus negative) 8.08 2.02–32.2 < 0.01 4.68 0.66–32.7 0.11
Tumor size (> 2 cm versus ≤ 2 cm) 3.68 1.01–13.3 0.04 1.73 0.26–11.3 0.56
Lymphovascular invasion (positive versus negative) 1.98 0.43–9.04 0.37 1.57 0.21–11.5 0.65
Age (< 40 yr versus ≥ 40 yr) 0.35 0.01–8.04 0.51 0.35 0.001–122.9 0.72
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Fig. 3. Relapse-free survival in patients with tumor sizes > 2 cm 
and axillary lymph node metastasis. There is no difference be-
tween groups undergoing chemotherapy or not. But chemotherapy 
brings a longer relapse-free period.
Fig. 1. Relapse-free survival in patients with tumor sizes > 2 cm. 
There is no difference between groups undergoing chemotherapy 
or not.
Fig. 2. Relapse-free survival in patients with axillary lymph node 
metastasis. There is no difference between groups undergoing 
chemotherapy or not. 
risk factors (Table 4). Meanwhile, there were no signifi-
cant death risk factors (Table 4). In multivariate analysis, 
there were no significant relapse and death risk factors 
(Table 5).
 
Relapse-free survival 
The relapse-free survival rates of patients with significant 
risk factors were estimated for patients with or without 
chemotherapy. In 44 patients with tumor size > 2 cm, 16 
patients received chemotherapy. The 5-year relapse-free 
survival rate of the patients undergoing chemotherapy 
was estimated at 78.7%, whereas for those not undergo-
ing chemotherapy it was estimated at 86.6%. The differ-
ence was not significant (P = 0.40) (Fig. 1). 
 In 37 patients with positive lymph node status, 21 
patients received chemotherapy. The 5-year relapse-free 
survival rate of the patients undergoing chemotherapy 
was estimated at 82.5%, whereas for those not undergo-
ing chemotherapy it was estimated at 83.3%. The differ-
ence was also not significant (P = 0.45) (Fig. 2).
 In 20 patients with positive lymph node status and 
tumor size > 2 cm, 14 patients received chemotherapy. 
The 5-year relapse-free survival rate of the patients un-
dergoing chemotherapy was estimated at 78.7%, whereas 
for those not undergoing chemotherapy it was estimated 
at 33.3%. The difference were also not significant on log-
rank analysis (P = 0.21), but significant on Wilcoxon’s 
analysis (P = 0.02) (Fig. 3). These suggest earlier relapse 
Table 5. Relapse-free survival and overall survival in 140 patients with luminal A breast cancer (multivariate anal-
ysis)
 Relapse-free survival  Overall survival
 Multivariate analysis  Multivariate analysis
 Hazard 95% Confidence   P  Hazard 95% Confidence   P
 ratio interval value ratio interval value
Lymph node status (/1 involved node)  0.95 0.88–1.03 0.26 0.94 0.88–1.01 0.14
Tumor size (/1 cm) 0.88 0.68–1.15 0.37 0.89 0.69–1.15 0.39
Lymphovascular invasion (positive versus negative) 0.84 0.56–1.26 0.40 0.86 0.57–1.30 0.49
Age (/1 yr) 1.01 0.99–1.02 0.14 1.01 0.99–1.02 0.12
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were more frequent in non-chemotherapy group than 
chemotherapy group. 
  
 
DISCUSSION 
Using complementary DNA microarrays representing 
8102 human genes, Perou et al. defined 4 breast cancer 
subtypes (luminal/ER, HER2-overexpressing, basal-like 
and normal), based on gene expression patterns.6 Carley 
et al. subsequently classified 5 subtypes based on immu-
nohistochemical staining of various markers as follows: 
luminal A (ER+ and/or PR+, HER2–), luminal B (ER+ 
and/or PR+, HER2+), HER2 (ER–, PR–, HER2+), basal-
like (ER–, PR–, HER2–, CK5/6+ and/or HER1+) and an 
unclassified type, and also demonstrated the applicabil-
ity of this system to past classification systems based on 
gene microarray analysis.7 The clinical application of 
gene expression profiling is limited because the proce-
dure is technically difficult and expensive. Therefore, 
the consensus of the 12th St. Gallen Conference defined 
luminal A breast cancer as ER+ and/or PR+, HER2– 
tumors with a Ki-67 labeling index of < 14%.4  However, 
there was a lack of complete consensus on the threshold 
indication for administering chemotherapy to patients 
with luminal A breast cancer.4 It has been reported that 
Oncotype DX recurrence scores were high in 13% of pa-
tients with luminal A breast cancer.8 Among tamoxifen-
treated patients, patients with a low or intermediate 
recurrence score on the 21-gene assay benefited from 
tamoxifen, whereas patients with a high recurrence 
score did not benefit.9 However, the 21-gene assay has 
also demonstrated that chemotherapy provided a large 
benefit when the recurrence score was high.10 These re-
sults suggest that chemotherapy is beneficial for patients 
with potentially malignant luminal A breast cancer.
 The value of chemotherapy for patients with large 
luminal A breast tumors is unclear. The 21-gene recur-
rence score assay has shown that there is a significant as-
sociation between increased tumor size and high recur-
rence score.10 Tumor size was prognostic for local and 
distant relapse.11, 12 These findings suggest that the larger 
the tumor the greater the association of gene expression 
with malignant potential and that chemotherapy may 
lead to a better prognosis. However, in our study, chemo-
therapy had no beneficial effects on relapse in patients 
with tumors larger than 2 cm. 
 The value of chemotherapy for patients with lymph 
node involvement of luminal A breast cancer is also not 
clear. Generally speaking, the number of axillary lymph 
node metastases is the most reliable prognostic factor 
and an important indication for adjuvant therapy. The 
addition of a paclitaxel protocol after the completion 
of anthracycline treatment has improved the disease-
free and OS of patients with node-positive early breast 
cancer.13, 14 However, patients with luminal A breast 
cancer benefit less from treatment with a taxane when 
administered after anthracycline, even if lymph nodes 
are involved.2, 3 In our study, chemotherapy had no ben-
eficial effects on relapse in patients with lymph node in-
volvement. The effects on relapse in patients with large 
tumor size and lymph node involvement were also not 
beneficial. Multivariate analysis revealed that endocrine 
therapy alone sufficiently removed relapse and death risk 
from patients with luminal A breast cancer. 
 The following reasons could explain why, in our 
study, patients with larger tumors and lymph node in-
volvement did not benefit from chemotherapy. First, mi-
croarray analysis has shown that nodal status and tumor 
size cannot be correlated with biologically distinct dis-
eases.15 These findings suggest that biological character-
istics, not node positivity, are indications for the use of 
chemotherapy.4 Therefore, in our study, luminal A breast 
cancer in patients with larger tumors and lymph node 
involvement may exhibit lower malignant potential. Sec-
ond, the chemotherapy regimen used in this study was at 
the lower limit of standard regimens in regard to dosages 
(epirubicin: 60–100 mg/m2, docetaxel: 60–100 mg/m2, 
paclitaxel: 80–100 mg/m2). A less-efficacious regimen 
might be the reason that we did not detect a significant 
effect in the chemotherapy group. Third, the size of this 
study is a limitation. Our study is retrospective, and the 
chemotherapy group contained 24 patients. We cannot 
draw a conclusion using such a small dataset. Fourth, 
unknown cases regarding nuclear grade and/or Ki-67 
could affect the results. In our study, nuclear grade in 
34 patients was unknown because the grading is gener-
ally used in patients with invasive ductal carcinoma and 
there is no consensus to decide nuclear grade in patients 
with special types of breast cancer. Ki-67 in 122 patients 
was unknown because it was introduced in May 2009, 
and the confidence for specimens embedded in paraf-
fin and preserved for long time is not established. Ki-67 
and/or nuclear grade are important factors to distinguish 
luminal A and luminal B (HER2 negative type) in the 
12th St. Gallen International Breast Cancer Conference 
held in 2011. Among them, the cases belonging to lu-
minal B (HER2 negative type) could be included and it 
may influence the result in patients with large tumor size 
and lymph node involvement. 
 In conclusion, chemotherapy could provide little 
benefit to patients with luminal A breast cancer, even 
those with high relapse risk factors including large tumor 
size and many positive nodes. However, chemotherapy 
may bring patients longer relapse-free periods. Prospec-
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tive studies and additional subject recruitment are neces-
sary to draw definitive conclusions. 
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